SPIE SA : The technical configuration is positive
BUY
Repli_rebond
Target price hit
Entry price | Target | Stop-loss | Potential |
---|
€14.25 |
€17 |
€12.75 |
+19.3% |
---|
The underlying tendency is to the upside for shares in SPIE SA and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Summary● In a short-term perspective, the company has interesting fundamentals.
Strengths● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.58 for the 2020 fiscal year.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● The company does not generate enough profits, which is an alarming weak point.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.